US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Subscribe To Our Newsletter & Stay Updated
